PTGER4 and sarcopenia: Healthy subjects at age 25–30 and above 50 years old were characterized by a significantly lower mRNA level of PTGER4 in comparison with all analyzed groups of patients (geriatric control, patients with frailty syndrome and sarcopenia) (Figure 3C).